{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:03:53Z","timestamp":1790521433713,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012331","name":"Flanders Innovation & Entrepreneurship","doi-asserted-by":"publisher","award":["HBC.2020.3239"],"award-info":[{"award-number":["HBC.2020.3239"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.tox.2025.154119","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:24:13Z","timestamp":1742232253000},"page":"154119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity"],"prefix":"10.1016","volume":"514","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-5630","authenticated-orcid":false,"given":"Annika","family":"Drees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-9337","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Tabernilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-1075","authenticated-orcid":false,"given":"Emmanuel","family":"Gustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"dos Santos Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-6464","authenticated-orcid":false,"given":"Darren Michael","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9810-6024","authenticated-orcid":false,"given":"Ann","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5672-0048","authenticated-orcid":false,"given":"Freddy","family":"Van Goethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-2752","authenticated-orcid":false,"given":"Julen","family":"Sanz-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2025.154119_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4254\/wjh.v16.i2.186","article-title":"Recent advances in the diagnosis of drug-induced liver injury","volume":"16","author":"Ahmed","year":"2024","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.tox.2025.154119_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/toxsci\/kfad015","article-title":"Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury","volume":"192","author":"Ali","year":"2023","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/toxsci\/kfv041","article-title":"Comparative localization and functional activity of the main hepatobiliary transporters in HepaRG cells and primary human hepatocytes","volume":"145","author":"Bachour-El Azzi","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib4","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1124\/dmd.116.071373","article-title":"Early alterations of bile canaliculi dynamics and the rho kinase\/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis","volume":"44","author":"Burbank","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154119_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for bayesian multilevel models using stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.tox.2025.154119_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.taap.2013.10.032","article-title":"Hepatocyte-based in vitro model for assessment of drug-induced cholestasis","volume":"274","author":"Chatterjee","year":"2014","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.tox.2025.154119_bib7","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tox.2025.154119_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yrtph.2018.04.018","article-title":"A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans","volume":"96","author":"Clark","year":"2018","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.tox.2025.154119_bib9","first-page":"73","article-title":"Drug-induced Liver Injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol. Hepatol. Rev."},{"key":"10.1016\/j.tox.2025.154119_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14744\/hf.2024.2024.0011","article-title":"New classification of drug induced liver injury (DILI) in AASLD guidance: What is next?","author":"Ercin","year":"2024","journal-title":"Hepatol. Forum 5"},{"key":"10.1016\/j.tox.2025.154119_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2023.104465","article-title":"Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach","volume":"145","author":"van Ertvelde","year":"2023","journal-title":"J. Biomed. Inf."},{"key":"10.1016\/j.tox.2025.154119_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med (Lond. )"},{"key":"10.1016\/j.tox.2025.154119_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.fct.2018.07.017","article-title":"Advances in drug-induced cholestasis: clinical perspectives, potential mechanisms and in vitro systems","volume":"120","author":"Fernandez-Murga","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(01)00460-7","volume":"167","author":"Funk","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2025.154119_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112165","article-title":"Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals","volume":"152","author":"Gijbels","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00204-019-02437-2","article-title":"Mechanisms and in vitro models of drug-induced cholestasis","volume":"93","author":"Gijbels","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib17","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.3748\/wjg.15.3134","article-title":"Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease","volume":"15","author":"Gnewuch","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tox.2025.154119_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/j.gastro.2015.02.050","article-title":"Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system","volume":"148","author":"Goldberg","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tox.2025.154119_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4939-9420-5_19","article-title":"Setup and use of HepaRG cells in cholestasis research","volume":"1981","author":"Guguen-Guillouzo","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2025.154119_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/toxsci\/kft021","article-title":"3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies","volume":"133","author":"Gunness","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep35434","article-title":"Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability","volume":"6","author":"Hendriks","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2025.154119_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/dmd.30.8.944","article-title":"Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver","volume":"30","author":"Honma","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154119_bib23","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J. Med Chem."},{"key":"10.1016\/j.tox.2025.154119_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2131\/jts.42.427","article-title":"Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics","volume":"42","author":"Kawamoto","year":"2017","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib25","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.1222","article-title":"Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury Risk? An international transporter consortium perspective","volume":"104","author":"Kenna","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.tox.2025.154119_bib26","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1124\/dmd.108.024778","article-title":"Effect of membrane cholesterol on BSEP\/Bsep activity: species specificity studies for substrates and inhibitors","volume":"37","author":"Kis","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154119_bib27","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1021\/mp300171p","article-title":"Expression and transport function of drug uptake transporters in differentiated HepaRG cells","volume":"9","author":"Kotani","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tox.2025.154119_bib28","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.tox.2025.154119_bib29","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/acs.chemrestox.6b00262","article-title":"Inhibition of hepatobiliary transport activity by the antibacterial agent fusidic acid: insights into factors contributing to conjugated hyperbilirubinemia\/cholestasis","volume":"29","author":"Lapham","year":"2016","journal-title":"Chem. Res Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.tiv.2013.07.003","article-title":"Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells","volume":"27","author":"Le Vee","year":"2013","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2025.154119_bib31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1021\/acs.chemrestox.2c00381","article-title":"Assessment of Drug-Induced Liver Injury through Cell Morphology and Gene Expression Analysis","volume":"36","author":"Lejal","year":"2023","journal-title":"Chem. Res Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the Dependency of Cellular Protein Levels on mRNA Abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tox.2025.154119_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2010.04.013","article-title":"HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro","volume":"63","author":"Lubberstedt","year":"2011","journal-title":"J. Pharm. Toxicol. Methods"},{"key":"10.1016\/j.tox.2025.154119_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/toxsci\/kfp088","article-title":"Toxicity testing in the 21st century: a view from the pharmaceutical industry","volume":"110","author":"MacDonald","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib35","first-page":"273","article-title":"The probable future of toxicology - probabilistic risk assessment","volume":"41","author":"Maertens","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.tox.2025.154119_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47114-7","article-title":"Three-dimensional HepaRG spheroids as a liver model to study human genotoxicity in vitro with the single cell gel electrophoresis assay","volume":"9","author":"Mandon","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2025.154119_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*\u200957:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2025.154119_bib38","unstructured":"NIH (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. In: Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/."},{"key":"10.1016\/j.tox.2025.154119_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tiv.2016.03.008","article-title":"Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes","volume":"34","author":"Oorts","year":"2016","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2025.154119_bib40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.24229","article-title":"Drug-induced cholestasis","volume":"53","author":"Padda","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2025.154119_bib41","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00204-017-1930-0","article-title":"Evaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes","volume":"91","author":"Parmentier","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.toxlet.2018.06.1069","article-title":"Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent","volume":"295","author":"Parmentier","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tox.2025.154119_bib43","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21359","article-title":"Hepatobiliary transporters and drug-induced cholestasis","volume":"44","author":"Pauli-Magnus","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2025.154119_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4939-9420-5_20","article-title":"Organotypic 3D HepaRG liver model for assessment of drug-induced cholestasis","volume":"1981","author":"Ramaiahgari","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2025.154119_bib45","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1016\/j.jchromb.2009.09.038","article-title":"Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry","volume":"877","author":"Scherer","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.tox.2025.154119_bib46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kfv136","article-title":"Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication","volume":"147","author":"Sison-Young","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib47","first-page":"371","article-title":"Ticlopidine-induced cholestatic hepatitis","volume":"37","author":"Skurnik","year":"2003","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.tox.2025.154119_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2024.503835","article-title":"In vitro hepatic 3D cell models and their application in genetic toxicology: a systematic review","volume":"900","author":"\u0160tampar","year":"2024","journal-title":"Mutat. Res Genet Toxicol. Environ. Mutagen"},{"key":"10.1016\/j.tox.2025.154119_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/17425255.2021.1854726","article-title":"Genetic risk factors in the development of idiosyncratic drug-induced liver injury","volume":"17","author":"Stephens","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep4.1088","article-title":"Drug-induced cholestasis","volume":"1","author":"Sundaram","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tox.2025.154119_bib51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/10915818231189659","article-title":"Recent advances in drug discovery toxicology","volume":"42","author":"Tang","year":"2023","journal-title":"Int J. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/cells8020192","article-title":"In-depth proteome analysis highlights HepaRG cells as a versatile cell system surrogate for primary human hepatocytes","volume":"8","author":"Tascher","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.tox.2025.154119_bib53","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/jat.3644","article-title":"Species differences in bile acids I. Plasma and urine bile acid composition","volume":"38","author":"Thakare","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drudis.2019.09.022","article-title":"Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity","volume":"25","author":"Thakkar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tox.2025.154119_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2020.101080","article-title":"Drug-induced cholestasis assay in primary hepatocytes","volume":"7","author":"Van Brantegem","year":"2020","journal-title":"MethodsX"},{"key":"10.1016\/j.tox.2025.154119_bib56","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.3390\/ijms222011005","article-title":"Primary human hepatocyte spheroids as tools to study the hepatotoxic potential of non-pharmaceutical chemicals","volume":"22","author":"Vilas-Boas","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kft177","article-title":"Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury","volume":"136","author":"Vinken","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tox.2025.154119_bib59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcpt.12449","article-title":"Bile acid-induced toxicity in HepaRG cells recapitulates the response in primary human hepatocytes","volume":"118","author":"Woolbright","year":"2016","journal-title":"Basic Clin. Pharm. Toxicol."},{"key":"10.1016\/j.tox.2025.154119_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/FPC.0b013e32832bcf7b","article-title":"Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans","volume":"19","author":"Xiang","year":"2009","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.tox.2025.154119_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbi.2004.09.011","article-title":"Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential","volume":"150","author":"Xu","year":"2004","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.tox.2025.154119_bib62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","article-title":"Cellular imaging predictions of clinical drug-induced liver injury","volume":"105","author":"Xu","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154119_bib63","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1124\/mol.112.081752","article-title":"Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites","volume":"83","author":"Yoshikado","year":"2013","journal-title":"Mol. Pharm."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:14:04Z","timestamp":1744370044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X25000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":63,"alternative-id":["S0300483X25000757"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2025.154119","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2025.154119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154119"}}